Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Blueprint Medicines Corp
(NQ:
BPMC
)
95.70
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Blueprint Medicines Corp
< Previous
1
2
3
4
5
6
Next >
10 Biggest Price Target Changes For Wednesday
June 01, 2022
Keybanc cut Ambarella, Inc. (NASDAQ: AMBA) price target from $160 to $120. Ambarella shares fell 5% to $81.00 in pre-market trading.
Via
Benzinga
What 3 Analyst Ratings Have To Say About Blueprint Medicines
May 19, 2022
Blueprint Medicines (NASDAQ:BPMC) has observed the following analyst ratings within the last quarter:
Via
Benzinga
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs
May 03, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
Blueprint Medicines: Q1 Earnings Insights
May 03, 2022
Blueprint Medicines (NASDAQ:BPMC) reported its Q1 earnings results on Tuesday, May 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Earnings Scheduled For February 16, 2022
February 16, 2022
Companies Reporting Before The Bell • Wix.com (NASDAQ:WIX) is projected to report quarterly loss at $0.38 per share on revenue of $331.16 million.
Via
Benzinga
EMA's Advisory Committee Recommends Approval Of Blueprint Medicines' Avapritinib In Blood Disorder
January 28, 2022
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has
Via
Benzinga
Analyst Ratings For Blueprint Medicines
January 25, 2022
Analysts have provided the following ratings for Blueprint Medicines (NASDAQ:BP...
Via
Benzinga
Earnings Preview: Blueprint Medicines
May 02, 2022
Blueprint Medicines (NASDAQ:BPMC) is set to give its latest quarterly earnings report on Tuesday, 2022-05-03. Here's what investors need to know before the announcement. Analysts estimate that...
Via
Benzinga
Blueprint Medicines Q1 2022 Earnings Conference Call On May 3, 2022 At 08:30 AM ET
April 27, 2022
Blueprint Medicines (NASDAQ:BPMC) will host a conference call at 08:30 AM ET on May 3, 2022, to discuss Q1 2022 earnings results.
Via
Benzinga
Where Blueprint Medicines Stands With Analysts
April 13, 2022
Over the past 3 months, 6 analysts have published their opinion on Blueprint Medicines (NASDAQ:BPMC) stock. These analysts are typically employed by large Wall Street banks and tasked with...
Via
Benzinga
After Encouraging Data, Blueprint Medicines Plans Combination Cohort In Tagrisso Resistant Lung Cancer
April 11, 2022
Blueprint Medicines Corp (NASDAQ: BPMC)
Via
Benzinga
Wednesdays With Wedbush: 3 Smid-Cap Biotech Stock Picks
March 09, 2022
Since the coronavirus pandemic began in early 2020, the FDA's plate has been full with reviews of COVID-19 vaccines and treatments. That has put the approval of many...
Via
Benzinga
What 5 Analyst Ratings Have To Say About Blueprint Medicines
March 01, 2022
Over the past 3 months, 5 analysts have published their opinion on Blueprint Medicines (NASDAQ:BPMC) stock. These analysts are typically employed by large Wall Street banks and...
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
March 01, 2022
During Tuesday's trading, 98 companies set new 52-week lows. Intriguing Points From Today's 52-Week Lows And Highs: JPMorgan Chase (NYSE:JPM) was the...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2022
March 01, 2022
Upgrades Stifel upgraded the previous rating for Revolution Medicines Inc (NASDAQ:RVMD) from Hold to Buy. For the fourth quarter, Revolution Medicines had an EPS of $0.71,...
Via
Benzinga
Blueprint Medicines, Proteovant Collaboration For Protein Degrader Therapies
February 28, 2022
Blueprint Medicines Corporation (NASDAQ: BPMC) and Proteovant Therapeutics have entered a strategic collaboration for targeted protein degrader therapies....
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
February 25, 2022
During Friday's trading, 54 companies set new 52-week lows. Things to Consider About Today's 52-Week Lows: The largest company by market cap to hit a new 52-week...
Via
Benzinga
Stocks That Hit 52-Week Lows On Monday
February 28, 2022
On Monday morning, 66 companies achieved new lows for the year. Noteable 52-Week Lows: Gilead Sciences (NASDAQ:GILD) was the largest firm on a market cap basis to set a...
Via
Benzinga
Where Blueprint Medicines Stands With Analysts
February 17, 2022
Over the past 3 months, 5 analysts have published their opinion on Blueprint Medicines (NASDAQ:BPMC) stock. These analysts are typically employed by large Wall Street banks and...
Via
Benzinga
The Daily Biotech Pulse: Avenue Tumbles On Negative Adcom Verdict, Moderna's Expanded Deal With Rovi, Gilead Takes Equity Stake In Hookipa
February 16, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Hookipa Gets $15M Upfront Payment And Equity Investment From Gilead Following...
Via
Benzinga
Earnings Preview: Blueprint Medicines
February 15, 2022
Blueprint Medicines (NASDAQ:BPMC) is set to give its latest quarterly earnings report on Wednesday, 2022-02-16. Here's what investors need to know before the announcement. Analysts estimate that...
Via
Benzinga
The Week Ahead In Biotech (Feb. 13-19): Agios FDA Meeting, Avenue Adcom, Earnings And More
February 13, 2022
Biotech stocks moved back and forth amid some volatility before finishing the week ending Feb. 11 modestly lower, reversing the gains from the previous week. Earnings news...
Via
Benzinga
10 Biggest Price Target Changes For Tuesday
January 25, 2022
Needham cut Medtronic plc (NYSE:MDT) price target f...
Via
Benzinga
Biotech Bloodbath Continues Despite Gene-Editing Deals For Pfizer, Bayer
January 10, 2022
Pfizer and Bayer inked deals with several companies in gene-editing.
Via
Investor's Business Daily
50 Biggest Movers From Yesterday
January 06, 2022
Gainers Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) shares surged 63.7% to settle at $2.21 on Wednesday after the company announced that in preclinical studies its lead...
Via
Benzinga
34 Stocks Moving In Wednesday's Mid-Day Session
January 05, 2022
Gainers Mainz Biomed B.V. (NASDAQ: MYNZ) shares climbed 49.7% to $15.45 after the company announced it acquired exclusive rights to novel mRNA biomarkers. Data Storage...
Via
Benzinga
Blueprint Medicines Expands Precision Therapy With Lengo Therapeutics Acquisition
November 29, 2021
Blueprint Medicines Corporation (NASDAQ: BPMC) has agreed to acquire Lengo Therapeutics, a privately held precision oncology company. The deal consideration...
Via
Benzinga
Week In Review: Zai Lab Announces Two In-Licensings With Total Value Of $800 Million
November 13, 2021
Shanghai Zai Lab announced two major in-licensings: a $615 million deal for two cancer drugs from Blueprint Medicines and a $187 million agreement for a psychiatric drug from Karuna Therapeutics.
Via
Talk Markets
Zai Lab Inks Back To Back Licensing Agreements For Cancer And Psychiatric Candidates
November 09, 2021
Zai Lab Limited (NASDAQ: ZLAB) and Blueprint Medicines Corporation (NASDAQ: BPMC) have announced an exclusive collaboration and license agreement in...
Via
Benzinga
Blueprint Medicines Corp (BPMC) Q3 2021 Earnings Call Transcript
October 28, 2021
BPMC earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.